HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration
The new funds of €15 million will be used to advance the clinical development of the Company’s clinical candidate HRX-215.
HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell
Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, researchers from the Mayo Clinic in Rochester (USA) and HepaRegeniX.